Pharmacological Strategies for the Treatment of Restless Legs Syndrome.

PURPOSE OF REVIEW: Restless legs syndrome (RLS) significantly impacts patients’ quality of life and requires effective management strategies. While dopaminergic agonists have been widely used in the past, concerns about symptom augmentation highlight the need for alternative therapies. RECENT FINDINGS: Non-dopaminergic agents, such as α2δ ligands and iron supplementation, are viable alternatives with favorable safety profiles. A comprehensive approach that includes non-pharmacological measures, individualized treatment plans, and regular monitoring for iron deficiency is essential for optimal symptom management. We present a treatment plan using iron replacement and long-term use of non-dopaminergic agents. Dopamine agonists are reserved for specific, time-limited situations only, while opioids should be kept for treatment-resistant cases. As research advances, future RLS management will likely be individualized, further enhancing therapeutic outcomes and ultimately improving patients’ overall quality of life.